NICE recommends inhaled antibacterials in cystic fibrosis

Inhaled formulations of two antibiotics can be prescribed on the NHS for patients with cystic fibrosis, NICE has ruled.

The primary cause of death in cystic fibrosis is respiratory failure precipitated by chronic pulmonary infection caused by Pseudomonas aeruginosa (pictured) | SCIENCE PHOTO LIBRARY
The primary cause of death in cystic fibrosis is respiratory failure precipitated by chronic pulmonary infection caused by Pseudomonas aeruginosa (pictured) | SCIENCE PHOTO LIBRARY

The tobramycin dry powder inhaler (TOBI Podhaler) is recommended for treating chronic pulmonary infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis.

Patients are eligible for treatment if nebulised tobramycin is considered appropriate, ie, colistimethate sodium is contraindicated, is not tolerated or has not produced an adequate response, and only if the manufacturer supplies the product with the discount agreed as part of the patient access scheme.

NICE also recommends colistimethate sodium powder for inhalation (Colobreathe) for patients with chronic P. aeruginosa infection who would benefit from continued colistimethate treatment but who do not tolerate the drug in nebulised form and would therefore be considered for tobramycin therapy. Again, NICE has specified that the drug must be provided with the discount agreed as part of the patient access scheme. However, Colobreathe has yet to be launched in the UK.

NICE guidance on inhaled tobramycin and colistimethate

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more